"T1: iso- to hypointense to cortex"
"T1 C+ (Gd): vivid contrast enhancement"
"DWI/ADC: low ADC values (due to high cellularity)"
"For a general discussion of systemic disease, please refer to the PTLD article."
"Clinical presentation is variable, and can occur over a wide range of time after transplantation; typically a few years, but the reported range is from 3 months to 11 years 1. As the inclusion of the term ‘primary’ in the name suggests, CNS involvement in PTLD is usually isolated to the central nervous system without evidence of systemic disease 1,2."
"The vast majority of cases are monoclonal tumours of B-cell origin, and many are Epstein-Barr virus-positive, similar to PCNS lymphoma encountered in HIV-positive patients 1. Polymorphic (P-PTLD) and plasmacytic hyperplasia, both seen with greater frequency in the periphery, are uncommon intracranially 1."
"Although uncommon, PCNS-PTLD represents the third most common CNS disorder in patients who have transplants; cerebrovascular disease and infection are more common 1. Autopsy-based series have identified PCNS-PTLD in 2-7% of patients. However, only a small subset of these patients would have had clinical evidence of disease 1."
"PCNS-PTLD was seen more commonly when azathioprine-based immunosuppression was widespread; with the introduction of newer agents (e.g. ciclosporin), the incidence of PCNS-PTLD has reduced 1,2."
"Clinical presentation is variable, and can occur over a wide range of time after transplantation; typically a few years, but the reported range is from 3 months to 11 years 1. As the inclusion of the term ‘primary’ in the name suggests, CNS involvement in PTLD is usually isolated to the central nervous system without evidence of systemic disease 1,2."
"On imaging PCNS-PTLD cannot readily be distinguished from non-transplant CNS lymphoma, especially in patients who are also immunocompromised, as they too tend to have multifocal disease and a greater propensity for central necrosis; both features are uncommon in non-immunocompromised patients with PCNS lymphoma 1."